194 related articles for article (PubMed ID: 22838843)
41. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
[TBL] [Abstract][Full Text] [Related]
42. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer.
Sakamoto T; Saito H; Amisaki M; Tokuyasu N; Honjo S; Fujiwara Y
Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):278-284. PubMed ID: 30987900
[TBL] [Abstract][Full Text] [Related]
43. [Surgical therapy of pancreatic cancer - 5 years survival].
Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
[TBL] [Abstract][Full Text] [Related]
44. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.
Park JY; King J; Reber H; Joe Hines O; Mederos MA; Wang HL; Dawson D; Wainberg Z; Donahue T; Girgis M
J Surg Oncol; 2021 Feb; 123(2):389-398. PubMed ID: 33146409
[TBL] [Abstract][Full Text] [Related]
45. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.
Chatterjee D; Katz MH; Rashid A; Wang H; Iuga AC; Varadhachary GR; Wolff RA; Lee JE; Pisters PW; Crane CH; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Am J Surg Pathol; 2012 Mar; 36(3):409-17. PubMed ID: 22301497
[TBL] [Abstract][Full Text] [Related]
46. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
47. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
[TBL] [Abstract][Full Text] [Related]
48. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
49. High-grade pancreatic intraepithelial lesions: prevalence and implications in pancreatic neoplasia.
Park JR; Li F; Oza VM; Sklaw BC; Cronley KM; Wellner M; Swanson B; Krishna SG
Hepatobiliary Pancreat Dis Int; 2017 Apr; 16(2):202-208. PubMed ID: 28381386
[TBL] [Abstract][Full Text] [Related]
50. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.
Stotz M; Eisner F; Szkandera J; Absenger G; Kornprat P; Lackner C; Samonigg H; Gerger A; Pichler M
J Clin Pathol; 2013 Sep; 66(9):753-7. PubMed ID: 23750038
[TBL] [Abstract][Full Text] [Related]
51. Can the new RCP R0/R1 classification predict the clinical outcome in ductal adenocarcinoma of the pancreatic head?
Janot MS; Kersting S; Belyaev O; Matuschek A; Chromik AM; Suelberg D; Uhl W; Tannapfel A; Bergmann U
Langenbecks Arch Surg; 2012 Aug; 397(6):917-25. PubMed ID: 22695970
[TBL] [Abstract][Full Text] [Related]
52. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis.
Yamamoto T; Yagi S; Kinoshita H; Sakamoto Y; Okada K; Uryuhara K; Morimoto T; Kaihara S; Hosotani R
World J Gastroenterol; 2015 Jan; 21(1):262-8. PubMed ID: 25574100
[TBL] [Abstract][Full Text] [Related]
53. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
[TBL] [Abstract][Full Text] [Related]
54. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122
[TBL] [Abstract][Full Text] [Related]
55. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
56. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.
Johnston WC; Hoen HM; Cassera MA; Newell PH; Hammill CW; Hansen PD; Wolf RF
HPB (Oxford); 2016 Jan; 18(1):21-8. PubMed ID: 26776847
[TBL] [Abstract][Full Text] [Related]
57. Clinicopathological and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma.
Lu J; Zhou L; Yang G; Liang ZY; Zhou WX; You L; Yuan D; Li BQ; Guo JC; Zhao YP
Hum Pathol; 2019 Apr; 86():143-154. PubMed ID: 30537492
[TBL] [Abstract][Full Text] [Related]
58. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
[TBL] [Abstract][Full Text] [Related]
59. Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer.
Chawla A; Huang TL; Ibrahim AM; Hardacre JM; Siegel C; Ammori JB
HPB (Oxford); 2018 May; 20(5):398-404. PubMed ID: 29221789
[TBL] [Abstract][Full Text] [Related]
60. Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer.
Xiao Y; Yang H; Lu J; Li D; Xu C; Risch HA
BMC Cancer; 2019 Oct; 19(1):1020. PubMed ID: 31664937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
